A recent report published by Infinium Global Research on the immunosuppressant drugs market provides an in-depth analysis of segments and
sub-segments in the global as well as regional immunosuppressant drugs market.
The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional immunosuppressant drugs market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecast and dollar values of the global immunosuppressant drugs market.
According to the report, the global immunosuppressant drugs market is projected
to grow at a CAGR of 4.9% over the forecast period of 2019-2025.
Immunosuppressant drugs are used in post organ transplants.
It has applications in the treatment of different autoimmune diseases such as
rheumatoid arthritis, multiple sclerosis, and psoriasis. After an organ
transplant, the immunity of patients has to be subdued to allow the patient’s
body to accept the newly planted organ. These are anti-rejection drugs that
make the body less likely to reject a transplanted organ such as the heart,
liver, or kidney.
The rise in the number of organ transplantation procedures
drives the growth of the immunosuppressant drugs market. As per the Global
Observatory on Donation and Transplantation report, there was 139024 organ
transplantation occurred in 2017. There is a significant increase in organ
transplantation procedures in recent years. The rising number of organ
transplantation for kidneys, lungs, liver, pancreas, and other organs led to
increasing demand for immunosuppressant drugs. Kidney is the most transplanted
organ globally. In 2017, 36% of the total number of transplantations was for
the kidney. Immunosuppressant drugs play a vital role in the success of organ
transplant procedures. Further, the growing prevalence of autoimmune disease
owing to changing lifestyles stimulates the expansion of the market. The
changes in dietary habits lead to stress, insufficient sleep, unhealthy eating
habits, smoking, and different environmental factors that promote the rise in
autoimmune diseases such as lupus, celiac disease, and others. The increasing
advancements in tissue engineering and organ transplant techniques promote the
growth of the immunosuppressant drugs market. Additionally, increasing
prevalence of chronic ailments and a rise in demand for organ replacement boost
the expansion of the immunosuppressant drugs market. On the flip side, the high
cost of the drugs restraints the growth of the immunosuppressant drugs market.
Moreover, the adoption of advanced medical treatments and the rising use of
tissue engineering create several opportunities for the growth of the
immunosuppressant drugs market.
Geographically, the global immunosuppressant drugs market is
divided into North America, Asia-Pacific, Europe, and the Rest of the World.
North America is expected to hold the largest share in the global
immunosuppressant drugs market. The growing prevalence of autoimmune diseases
and the increasing number of organ transplants in North America drive the
growth of the immunosuppressant drugs market in the region. A study estimated
that in the United States around 24 million people are having an autoimmune
disease. In addition, as of September 2019, the number of organ transplant
candidates in the United States is 112947. Europe is expected to grow in the
global immunosuppressant drugs market with a healthy CAGR over the forecast
period. The rising number of transplants in Europe contributes to the expansion
of the immunosuppressant drugs market in Europe. Asia-Pacific region has
lucrative growth opportunities in the global immunosuppressant drugs market
owing to the well-established healthcare industry and growing medical tourism
in the region.
The report on global immunosuppressant drugs market covers
segments such as drug type, route of administration, application, and end-user.
On the basis of drug type, the sub-markets include calcineurin inhibitors,
center for biotechnology, antiproliferative agents, imdh inhibitors, and other
drug types. On the basis of route of administration, the sub-markets include
intravenous, oral, and other routes. On the basis of application, the
sub-markets include organ transplant, autoimmune disease, kidney transplant, liver
transplant, heart transplant, and other applications. On the basis of end-user,
the sub-markets include organ transplant centers, hospitals and clinics, and
The report provides profiles of the companies in the market
such as Genzyme Corp., Astellas Pharma Inc., Accord Healthcare Ltd.,
Bristol-Myers Squibb Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals,
Inc., F. Hoffmann-La Roche AG, Mylan Laboratories Ltd., Pfizer Inc., Novartis
International AG, and Other companies.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of the immunosuppressant drugs market. Moreover, the study highlights current market
trends and provides forecast from 2019-2025. We also have highlighted future
trends in the market that will affect the demand during the forecast period.
Moreover, the competitive analysis given in each regional market brings an
insight into the market share of the leading players.